The potential risks of pancreatitis and pancreatic cancer with GLP‐1‐based therapies are far outweighed by the proven and potential (cardiovascular) benefits
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Recent suggestions that glucagon‐like peptide‐1 (GLP‐1)‐based therapies could cause pancreatitis, and even pancreatic cancer, are based on: Animal studies: The worrying histological changes are not reproduced in all studies and are unexpectedly variable with different GLP‐1‐based therapies. An observational study: Singh's findings that pancreatitis is doubled with GLP‐1‐based therapies could relate to their use in obese patients who are prone to pancreatitis risk factors—gallstones and hypertriglyceridaemia. The other observational studies do not find an association between GLP‐1‐based therapies and pancreatitis. US Food and Drug Administration adverse event reporting system: The increased reports of pancreatitis and pancreatic cancer are likely to be attributable to ‘notoriety bias’. A study of organ donor pancreases: Butler's findings for those on GLP‐1‐based therapies vs. those not, could have other explanations. Meanwhile: Meta analysis: Randomized control trials with GLP‐1‐based therapies do not find increased pancreatitis risk. Meta‐analysis of 53 randomized controlled trials including 20 212 dipeptidyl peptidase‐4 inhibitor‐treated patients found a significantly reduced risk of major adverse cardiovascular events [odds ratio 0.689 (0.528–0.899), P = 0.006] for dipeptidyl peptidase‐4 inhibitors compared with control subjects. Cardiovascular risk: The evidence suggests that there is more than a possibility that some of the GLP‐1 receptor agonists, and possibly also some dipeptidyl peptidase‐4 inhibitors, may be associated with reduced cardiovascular events. Eight ongoing long‐term cardiovascular randomized controlled trials will report from September 2013 onwards. These trials should resolve the issue of pancreatitis risk and substantiate the extent of benefit. Conclusion: Whilst we should remain vigilant, currently the balance of evidence is strongly in support of GLP‐1‐based therapy, with benefits far outweighing potential risks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699
Singh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. M. (2013) · Diabetes Care · doi:10.2337/dc12-2713 · Cited by 296
Bunck, M. C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R. M., Heine, R. J., Taskinen, M.-R., Yki-Järvinen, H., & Smith, U. (2010) · Diabetes Care · doi:10.2337/dc09-2361 · Cited by 161
White, W. B., Bakris, G. L., Bergenstal, R. M., Cannon, C. P., Cushman, W. C., Fleck, P., Heller, S., Mehta, C., Nissen, S. E., Perez, A., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.08.004 · Cited by 152
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Price, D. L., Chen, R., Udell, J., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.08.006 · Cited by 106
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
“Balance between Risks and Benefits The risks and benefits of incretin-based therapies have been discussed in several published papers [73, 191, 192].”
BackgroundAcute pancreatitis during GLP-1 receptor agonist treatment. A case report
Chis, B. A., & Fodor, D. (2018) · Medicine and Pharmacy Reports · doi:10.15386/cjmed-804 · Cited by 26
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
Metadata
- Authors
- Ryder, R. E. J.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2013-09-16
- Volume
- 30
- Issue
- 10
- Pages
- 1148-1155
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2103487864
- Cited by
- 41
- References
- 10
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The potential risks of pancreatitis and pancreatic cancer with GLP‐1‐based therapies are far outweighed by the proven and potential (cardiovascular) benefits. https://app.cochat.ai/papers/10.1111/dme.12301
- The paper
- Ryder, R. E. J. (2013). The potential risks of pancreatitis and pancreatic cancer with GLP‐1‐based therapies are far outweighed by the proven and potential (cardiovascular) benefits. Diabetic Medicine. https://doi.org/10.1111/dme.12301
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.